MENUMENU
  • Kontakt
  • Newsletter
  • DE
  • EN
  • FR
#SIPBB
MENUMENU
  • Forschung
        • Swiss Smart Factory
        • Swiss Advanced Manufacturing Center
        • Swiss MedTech Center
        • Swiss Battery Technology Center
  • Technologie
        • Engineering
        • Additive Fertigung
        • FABLAB & Elektrolabor
  • Raum
    • Heute
    • Morgen
  • Event
    • Events
      • Additive Update
      • Medtech Innovation Event
      • Digitaltag
      • Startup Weekend Biel/Bienne
      • FABLAB Events
      • Ihr Event
    • Workshops
      • Basiswissen Medtech Regulatory
      • Big Data
      • Weiterbildung für Konstrukteure
  • Startup
    • Accelerator
    • Incubator
  • Über uns
    • Mission
    • Downloads
    • Jobs & Karriere
    • Region
    • Partner und Sponsoren
    • Alle Standorte
    • Team
    • Trägerschaft
    • Verwaltungsrat
  • News
    • Newsroom
    • Presse
    • Success Stories
    • Wissenschaftliche Arbeiten

IPS Biopharma

#SIPBB
MENUMENU
  • Forschung
    • Swiss Smart Factory
    • Swiss MedTech Center
    • Swiss Advanced Manufacturing Center
    • Swiss Battery Technology Center
  • Technologie
    • Engineering
    • Additive Fertigung
    • FABLAB & Elektrolabor
  • Raum
    • Heute
    • Morgen
  • Event
    • Alle Events
    • Alle Workshops
  • Startup
    • Accelerator
    • Incubator
  • Über uns
    • Mission
    • Downloads
    • Jobs & Karriere
    • Region
    • Verwaltungsrat
    • Team
    • Partner und Sponsoren
    • Alle Standorte
  • News
    • Newsroom
    • Presse
    • Success Stories
  • Kontakt
  • Newsletter
  • EN
    • DE
    • FR

IPS Biopharma

Zurück zu Success Stories

27.01.2019

SHARE
Share on facebook
Share on twitter
Share on linkedin
Share on email
IPS Biopharma AG is a privately held, Swiss immuno-oncology focused biotech company developing a potentially first-in-class immunotherapy for solid tumor cancers. The company’s lead drug candidate, IP-001, is designed to initiate a patient-specific, well-tolerated, systemically active immune response against a patient’s individual cancer. IP-001, also known as N-dihydrogalactochitosan, is injected intratumorally after a standard-of-care tumor ablation to initiate the immunotherapy. Unique molecular properties and the novel mechanism of action enables IP-001 to trap and retain tumor-targeting information and promote a robust immune response that attacks both the ablated tumor and distant metastases.

Encouraging early clinical data showed shrinkage of both local tumors and distant metastases after ablation + IP-001 treatment. In some patients, this led to elimination of the cancer with long-lasting response. The company has partnered with the Swiss Group for Clinical Cancer Research (SAKK) for clinical trial development and implementation of its Swiss phase I/II multicenter study that addresses significant clinical unmet need in various indications.

IPS Biopharma AG is an Immunophotonics subsidiary and is supported by the Swiss Foundation for Technological Innovation (STI), be-advanced, the Berne Economic Development Agency (BEDA), is located in the Switzerland Innovation Park and is an active part of the startup community in Switzerland.

ips-Biopharma a new additional way for cancer treatment
IPS Biopharma treatment diagram
Zurück
Weiter

Mehr News

Loading...
02.03.2021

Die ganzheitliche Lösung für die «letzte Meile Logistik»

Das Berner Jung­unternehmen «Rikscha Taxi Schweiz AG» entwickelt Elektrofahrzeuge für die «letzte Meile Logistik» in Stadtzentren.
Mehr erfahren
15.01.2021

Every crisis is also a chance

It becomes clear that all the technologies on which we have been working on under the concept of "Industry 4.0"...
Mehr erfahren
18.12.2020

Merry Christmas and an Innovative New Year!

Der Switzerland Innovation Park Biel/Bienne bleibt vom Donnerstag, 24. Dezember 2020 bis Sonntag, 3. Januar 2021 geschlossen
Mehr erfahren

HOLEN SIE SICH IHREN PERSONALISIERTEN NEWSLETTER

REGISTRIEREN
FACEBOOK
Twitter
Linkedin
Youtube
Instagram

Kontakt

Switzerland Innovation
Park Biel/Bienne AG
Aarbergstrasse 46
2503 Biel/Bienne
info@sipbb.ch
+41 32 530 88 88

E-MAil
Anrufen
Karte

Alle Standorte

PARK BASEL AREA
switzerland-innovation.com/baselarea

PARK INNOVAARE

switzerland-innovation.com/innovaare

PARK ZURICH
switzerland-innovation.com/zurich

NETWORK WEST EPFL

switzerland-innovation.com/network-west

Datenschutz

Impressum

 © 2021 Switzerland Innovation Park Biel/Bienne

This website uses cookies to ensure you get the best experience on our website. By continuing you agree with the our terms of use.

got it